Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Neobo Fastigheter in connection with the listing of Neobo Fastigheter’s shares on Nasdaq First North Premier
Mandate

Vinge has advised Neobo Fastigheter in connection with the listing of Neobo Fastigheter’s shares on Nasdaq First North Premier

February 10, 2023 Capital Markets and Public M&A Corporate Tax

Vinge has advised Neobo Fastigheter AB (publ) (”Neobo”) in connection with the listing of Neobo’s shares on Nasdaq First North Premier. The company description was published on 6 February 2023 and the first day of trading on Nasdaq First North Premier was on 10 February 2023.

Neobo is a property company that long-term manages and refines rental properties all over Sweden. The property portfolio consists of 8,381 apartments distributed over 268 properties, with a total property value of SEK 15.3 billion as of 31 December 2022. The company’s business model is to manage and refine residential properties in municipalities with population growth, good employment rate and a stable rental market.

Vinge’s team consisted of Jesper Schönbeck, Rikard Lindahl, Joel Magnusson, Johannes Akyol, Gabriel Chabo, Clara Sohlberg, Kristoffer Larson, Victor Ericsson and Maria Schultzberg.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026